BlackRock Added To The FFJ Portfolio

A good time to initiate a BlackRock, Inc. (BLK) position would have been in late September/early October. However, due to an unexpected opportunity disclosed in my FFJ Portfolio – September 2022 Report, I regretfully had to remain on the sidelines. By the time my liquidity had improved, BLK's share price had rocketed higher and its [...]

FFJ Portfolio – February 2023 Report

This brief FFJ Portfolio - February 2023 Report is an overview of recent activity. I remain cautious about the broad market conditions and made no purchases during the month. Exited Positions After reviewing Stryker Corporation (SYK) I disclosed my decision to exit this position in this February 8, 2023 post; I have not redeployed the [...]

Home Depot Is Overvalued Despite the Recent Share Price Pullback

On February 21, Home Depot (HD) released Q4 and FY2022 results (January 29, 2023 FYE) and FY2023 guidance. Management expects 2023 to be a year of moderation and is targeting approximately flat comp sales and a mid-single-digit percent decline in diluted EPS compared to the prior fiscal year. This guidance has not been well received [...]

By |February 22nd, 2023|Equity Investing|Comments Off on Home Depot Is Overvalued Despite the Recent Share Price Pullback

Rollins – Pests Are Indifferent To Economic Conditions

Fortunately for Rollins (ROL), pests are indifferent to economic conditions. It generates ~80% recurring revenue and boats 20+ years of revenue growth. I last reviewed this holding in my November 19, 2022 post. With the release of FY2022 results following the February 15 market close, I revisit it to determine whether I should acquire additional [...]

By |February 20th, 2023|Equity Investing|Comments Off on Rollins – Pests Are Indifferent To Economic Conditions

West Pharmaceutical’s Valuation Is Unattractive

How times have changed after my November 25, 2022, Buy Out Of Favour West Pharmaceutical post! In that post, I noted that West Pharmaceutical's (WST) short-term headwinds had led to its valuation retracing to a reasonable level and that I had initiated a 100-share position @ ~$225/share in one of the 'Core' accounts within the [...]

By |February 17th, 2023|Equity Investing|Comments Off on West Pharmaceutical’s Valuation Is Unattractive

S&P Global – Attractive Long-Term Outlook Despite Short-Term Ratings Division Headwinds

I last reviewed S&P Global (SPGI) in my October 31, 2022 post at which time I considered shares to be attractively valued. It continues to have an attractive long-term outlook despite short-term Ratings Division headwinds. However, shares are not attractively valued. I like to accumulate shares in great companies when they experience short-term headwinds; SPGI [...]

By |February 10th, 2023|Equity Investing|Comments Off on S&P Global – Attractive Long-Term Outlook Despite Short-Term Ratings Division Headwinds
Go to Top